4. CONCLUSION
We present a rare case of IDDVT
that was potentially attributed to adenomyosis-associated
hypercoagulability and travel-related blood stasis. This case study
highlights the importance of etiologic investigation and treatment in
the management of thrombotic complications. A comprehensive analysis of
previously documented cases suggests that CA125 may serve as a promising
biomarker for predicting recurrent or systemic thromboembolism in
patients with adenomyosis. Additionally, it is noteworthy that the risk
window for thrombotic events in patients with adenomyosis may extend
beyond the menstrual period, suggesting a longer duration of
susceptibility. Therefore, adenomyosis should be regarded as a potential
risk factor for thromboembolism. Aggressive thrombotic risk assessment
should be considered as part of clinical practice for patients with this
condition, particularly those presenting with severe symptoms and
significantly elevated CA125 levels.